SAB Biotherapeutics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY June 30, 2022 |
|---|---|---|---|---|---|
| Revenue | $0 | $1.3M | $2.2M | $23.9M | — |
| Operating income | -$49.0M | -$42.9M | -$38.1M | -$28.9M | — |
| Operating expenses | $49.0M | $44.2M | $40.3M | $52.8M | — |
| Cash from operations | -$44.8M | -$34.3M | -$25.1M | -$23.5M | — |
| Capital expenditure | $933,156 | $337,262 | $197,154 | $2.2M | — |
| Free cash flow | -$45.7M | -$34.6M | -$25.3M | -$25.6M | — |
| Impairments | $0 | $0 | $0 | $0 | — |
| Total assets | $172.8M | $44.2M | $83.9M | $50.9M | $59.4M |
| Total liabilities | $21.3M | $18.2M | $26.6M | $19.8M | $22.3M |
Shares outstanding 76.5M · Free float 74.4%
Annual filing data through FY ended December 31, 2025; float as of July 2, 2026.